Skip to content
Bored Studies
RecruitingAccepts healthy volunteers

Development of a Quantifiable Ultrasound Biomarker for Hepatic Steatosis

ContextVision AB · with University of Washington · NCT07270601

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–75 · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Not applicable
Target enrollment
110
US sites recruiting
1
Study start
November 17, 2025
Record last updated
December 8, 2025

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The research study is considering a non-invasive way to measure the percentage of fat in the liver using ultrasound. This could help detect early signs of a very common condition called metabolic dysfunction-associated steatotic liver disease (MASLD). Current tests, like MRI or biopsy, can be expensive or invasive. If successful, this ultrasound tool could become an easier and more accessible way to monitor liver health - especially for people with obesity, diabetes, high blood pressure, or high cholesterol.

Being studied: Verasonics NXT Data Acquisition System; Philips EPIQ Elite; EchoSense FibroScan; Philips 3T Ingenia Elition

Conditions: MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease; NAFLD - Non-Alcoholic Fatty Liver Disease

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

Diseased subject

  • Adult patients (age 18 - 75 years)
  • Consent to participate in the study
  • Diagnosed or suspected MASLD from the hepatology clinic, OR
  • High-risk population meeting the adult cardiometabolic criteria (defined as the presence of at least one of the following: diabetes, obesity (BMI ≥ 25 kg/m2), hypercholesterolemia, and hypertension)

Healthy volunteer

  • Adult patients (age 18 - 75 years)
  • Consent to participate in the study
  • No suspicion of MASLD by laboratory/imaging/clinical examinations
  • Absence of known pre-existing conditions (metabolic syndrome, diabetes mellitus, obesity, insulin resistance, dyslipidemia, etc.)

Exclusion Criteria

  • Pregnancy or nursing.
  • Contraindications to MRI including, but not limited to, severe claustrophobia, pacemaker, or existing metallic/mechanical implant(s).
  • Acute illness/cognitive impairment resulting in an inability to cooperate with the MRI and ultrasound breath-holding instructions.
  • BMI > 35 kg/m2
  • History of excessive alcohol consumption according to the updated MASLD criteria (>2 drinks/day OR >210 grams/week for males AND >1 drink/day OR >140 grams/week for females) or drug use over the past 2 years.
  • Known acute or chronic hepatitis; or other etiology of liver disease.
  • Presence of known congenital hepatic anomaly.
  • Known cirrhosis
  • Known active cancer

Recruiting US locations

  • University of Washington

    Seattle, WA 98195

    Site contact: Research Fellow · 206-616-0397 · madhvi@uw.edu

Study contacts (from the official record)

  • Laura Sissons-Ross Research Manager · 206-616-0397 · lsissons@uw.edu
All nutrition & metabolism studies in Washington →
Development of a Quantifiable Ultrasound Biomarker for Hepatic… (NCT07270601) | Bored Studies